title: Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
abstract: This fifteenth biannual report of the Cochrane Haematological Malignancies Group (CHMG) highlights recently published randomized controlled trials (RCTs) in the field of hemato-oncology, covering the publication period from October 2011 to May 2012. Implications for clinical practice and methodological aspects are the main principles for selecting trials for this report. Studies were identified by electronic search of MEDLINE using a broad search filter that covers all topics in hemato-oncology combined with a highly sensitive search filter for randomized trials (Cochrane Handbook for Systematic Reviews of Interventions).
authors.affiliation: Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. michaela.arancea@uk-koeln.de
authors.forename: Michaela
authors.initials: M
authors.lastname: Rancea
authors.forename: Andrea
authors.initials: A
authors.lastname: Will
authors.forename: Peter
authors.initials: P
authors.lastname: Borchmann
authors.forename: Ina
authors.initials: I
authors.lastname: Monsef
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
authors.forename: Nicole
authors.initials: N
authors.lastname: Skoetz
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides / Q000008:administration & dosage; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D000069439:Dasatinib; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009101:Multiple Myeloma / Q000188:drug therapy*; D009367:Neoplasm Staging; D010879:Piperazines / Q000008:administration & dosage; D017713:Platelet Transfusion; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011322:Primary Prevention; D011344:Procarbazine / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D013844:Thiazoles / Q000008:administration & dosage; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D014751:Vindesine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D001761:Bleomycin; D011344:Procarbazine; D000069283:Rituximab; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D000068877:Imatinib Mesylate; D003520:Cyclophosphamide; D000069439:Dasatinib; D014751:Vindesine; D011241:Prednisone